Published in PLoS One on November 14, 2012
Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface. Histochem Cell Biol (2016) 0.85
Stage-specific prognostic biomarkers in melanoma. Oncotarget (2015) 0.83
Revisiting determinants of prognosis in cutaneous melanoma. Cancer (2015) 0.77
Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis. Oncotarget (2015) 0.76
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
The significance of digital gene expression profiles. Genome Res (1997) 23.90
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet (2006) 16.12
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg (1970) 12.72
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Melanoma. N Engl J Med (2006) 8.80
Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst (2007) 7.44
Increasing burden of melanoma in the United States. J Invest Dermatol (2009) 4.43
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics (2008) 3.11
Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. J Biol Chem (2005) 2.88
REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol (2005) 2.82
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 2.32
Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res (2007) 2.15
A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res (2007) 2.11
Cross-validation in survival analysis. Stat Med (1993) 2.01
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res (2010) 2.01
Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol (2004) 2.01
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res (2008) 1.99
Integrative genome comparison of primary and metastatic melanomas. PLoS One (2010) 1.97
GeneAnnot: comprehensive two-way linking between oligonucleotide array probesets and GeneCards genes. Bioinformatics (2004) 1.92
CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood (1997) 1.89
High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene (2007) 1.83
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol (2012) 1.75
CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol (1991) 1.73
Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer (2009) 1.46
Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 1.44
Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res (2009) 1.40
Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) (2007) 1.35
Loss of profilin-1 expression enhances breast cancer cell motility by Ena/VASP proteins. J Cell Physiol (2009) 1.30
Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res (2008) 1.17
A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2005) 1.14
A gene expression signature associated with survival in metastatic melanoma. J Transl Med (2006) 1.13
Purification of neuronal precursors from the adult mouse brain: comprehensive gene expression analysis provides new insights into the control of cell migration, differentiation, and homeostasis. Mol Cell Neurosci (2004) 1.12
Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther (2011) 1.04
High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res (2010) 1.02
The new melanoma staging system. Cancer Control (2002) 1.01
A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res (2009) 1.01
The cooperation between hMena overexpression and HER2 signalling in breast cancer. PLoS One (2010) 1.01
EVL (Ena/VASP-like) expression is up-regulated in human breast cancer and its relative expression level is correlated with clinical stages. Oncol Rep (2008) 1.00
Rap1-GTP-interacting adaptor molecule (RIAM) protein controls invasion and growth of melanoma cells. J Biol Chem (2011) 1.00
Kinetics of gene expression profiling in Swiss 3T3 cells exposed to aqueous extracts of cigarette smoke. Carcinogenesis (2002) 0.99
Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression. Int J Oncol (2009) 0.96
Identifying tumor stem-like cells in mouse melanoma cell lines by analyzing the characteristics of side population cells. Cell Biol Int (2009) 0.93
Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol (2011) 0.93
Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. Int J Cancer (2008) 0.91
The ADMA/DDAH pathway regulates VEGF-mediated angiogenesis. Arterioscler Thromb Vasc Biol (2009) 0.91
Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis. J Invest Dermatol (2007) 0.89
Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients. Cancer Biother Radiopharm (2008) 0.84
Increased noise sensitivity and altered inner ear MENA distribution in VASP-/- mice. Cell Tissue Res (2004) 0.83
Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatol Ther (2005) 0.83
An embryo-specific expressing TGF-β family protein, growth-differentiation factor 3 (GDF3), augments progression of B16 melanoma. J Exp Clin Cancer Res (2010) 0.81
Biochemical analysis of the human ENA/VASP-family proteins, MENA, VASP and EVL, in homologous recombination. J Biochem (2011) 0.78
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity (2013) 2.79
Venous thrombosis after long-haul flights. Arch Intern Med (2003) 2.50
Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol (2010) 2.11
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res (2008) 1.99
Integrative genome comparison of primary and metastatic melanomas. PLoS One (2010) 1.97
Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J Invest Dermatol (2009) 1.75
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep (2013) 1.74
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer (2010) 1.66
Biphenotypic B-lymphoid/myeloid cells expressing low levels of Pax5: potential targets of BAL development. Blood (2012) 1.56
Merkel cell polyomavirus DNA in persons without merkel cell carcinoma. Emerg Infect Dis (2009) 1.45
Podoplanin expression in cutaneous head and neck squamous cell carcinoma--prognostic value and clinicopathologic implications. J Surg Oncol (2012) 1.44
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol (2006) 1.43
[Patients' view of melanoma follow-up]. J Dtsch Dermatol Ges (2004) 1.43
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol (2006) 1.41
EMPACT syndrome. J Dtsch Dermatol Ges (2005) 1.41
Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res (2008) 1.40
Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A (2011) 1.31
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
Mechanical tension and integrin alpha 2 beta 1 regulate fibroblast functions. J Investig Dermatol Symp Proc (2006) 1.26
Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J (2002) 1.22
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med (2013) 1.19
Type II keratins precede type I keratins during early embryonic development. Eur J Cell Biol (2005) 1.18
Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget (2012) 1.11
Blood-based gene expression signatures in non-small cell lung cancer. Clin Cancer Res (2011) 1.09
3-Layer-based analysis of peptide-MHC interaction: in silico prediction, peptide binding affinity and T cell activation in a relevant allergen-specific model. Mol Immunol (2009) 1.09
Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. Cancer Res (2005) 1.06
Loss of serum response factor in keratinocytes results in hyperproliferative skin disease in mice. J Clin Invest (2009) 1.03
A critical cross-validation of high throughput structural binding prediction methods for pMHC. J Comput Aided Mol Des (2009) 1.03
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother (2004) 1.03
The spatial pattern of coronary capillaries in patients with dilated, ischemic, or inflammatory cardiomyopathy. Cardiovasc Pathol (2005) 1.02
[AWMF Guideline no. 013/066. Diagnosis and therapy of circumscribed scleroderma]. J Dtsch Dermatol Ges (2009) 1.02
IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol (2011) 1.02
Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur J Clin Pharmacol (2009) 1.01
Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep (2013) 0.99
Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res (2006) 0.99
Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. J Invest Dermatol (2012) 0.99
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res (2010) 0.99
Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression. Int J Cancer (2004) 0.98
Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products. J Gen Virol (2005) 0.97
Role of ADAM-9 disintegrin-cysteine-rich domains in human keratinocyte migration. J Biol Chem (2007) 0.96
Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab (2009) 0.96
Ocular diseases in metastatic cutaneous melanoma: review of 108 consecutive patients in two German tertiary centers. Graefes Arch Clin Exp Ophthalmol (2014) 0.95
Dissociation of the complex between CD151 and laminin-binding integrins permits migration of epithelial cells. Exp Cell Res (2006) 0.95
Gab3-deficient mice exhibit normal development and hematopoiesis and are immunocompetent. Mol Cell Biol (2003) 0.94
A comparative approach linking molecular dynamics of altered peptide ligands and MHC with in vivo immune responses. PLoS One (2010) 0.94
c-Fos-dependent induction of the small ras-related GTPase Rab11a in skin carcinogenesis. Am J Pathol (2005) 0.93
Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood (2012) 0.93
Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases. J Am Acad Dermatol (2011) 0.92
Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol (2006) 0.91
Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. Int J Cancer (2008) 0.91
Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations. Haematologica (2010) 0.91
The invasive potential of human melanoma cell lines correlates with their ability to alter fibroblast gene expression in vitro and the stromal microenvironment in vivo. Int J Cancer (2009) 0.91
Identification and discrimination of extracellularly active cathepsins B and L in high-invasive melanoma cells. Anal Biochem (2006) 0.91
Delayed wound healing and epidermal hyperproliferation in mice lacking JunB in the skin. J Invest Dermatol (2006) 0.90
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer (2011) 0.90
Expression of matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and MT1-MMP in skin tumors of human papillomavirus type 8 transgenic mice. Exp Dermatol (2006) 0.90
Keratitis-ichthyosis-deafness syndrome in association with follicular occlusion triad. Eur J Dermatol (2005) 0.90
Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer (2005) 0.90
vmdICE: a plug-in for rapid evaluation of molecular dynamics simulations using VMD. J Comput Chem (2010) 0.90
Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur J Cell Biol (2004) 0.90
Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther (2012) 0.89
Expression of type I interferon by splenic macrophages suppresses adaptive immunity during sepsis. EMBO J (2011) 0.89
Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma. Cancer Lett (2004) 0.89
High-affinity Rb binding, p53 inhibition, subcellular localization, and transformation by wild-type or tumor-derived shortened Merkel cell polyomavirus large T antigens. J Virol (2013) 0.89
Loss of epidermal Evi/Wls results in a phenotype resembling psoriasiform dermatitis. J Exp Med (2013) 0.89
Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis. J Invest Dermatol (2007) 0.89
Optimized arterial trees supplying hollow organs. Med Eng Phys (2005) 0.89
Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNλ) in cutaneous lupus erythematosus. J Invest Dermatol (2010) 0.88
Bacteremia caused by a novel helicobacter species in a 28-year-old man with X-linked agammaglobulinemia. J Clin Microbiol (2010) 0.88
Epithelioid sarcoma with angiomatoid features: report of an unusual case arising in an elderly patient within a burn scar. J Cutan Pathol (2008) 0.88
High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1alpha and basic fibroblast growth factor-mediated mechanisms. J Invest Dermatol (2005) 0.88
Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J Invest Dermatol (2011) 0.87
Short German guidelines: Merkel cell carcinoma. J Dtsch Dermatol Ges (2008) 0.87
NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo. PLoS One (2013) 0.87
Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol (2002) 0.87
Polo-like kinase 1 is a potential therapeutic target in human melanoma. J Invest Dermatol (2011) 0.87
Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol (2014) 0.87
Side chain substitution benchmark for peptide/MHC interaction. Protein Sci (2008) 0.87
MT1-MMP cleaves Dll1 to negatively regulate Notch signalling to maintain normal B-cell development. EMBO J (2011) 0.86
Induction of durable responses by oral etoposide monochemotherapy in patients with metastatic Merkel cell carcinoma. Eur J Dermatol (2012) 0.86
Cis-9,trans-11-CLA exerts anti-inflammatory effects in human bronchial epithelial cells and eosinophils: comparison to trans-10,cis-12-CLA and to linoleic acid. Biochim Biophys Acta (2005) 0.86
Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res (2015) 0.86
Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges (2008) 0.86
MRI findings before and after prolapse surgery. Acta Radiol (2013) 0.86
Activated neutrophils exert antitumor activity against human melanoma cells: reactive oxygen species-induced mechanisms and their modulation by granulocyte-macrophage-colony-stimulating factor. J Invest Dermatol (2003) 0.86
Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression. Melanoma Res (2003) 0.86
Defective laminin 5 processing in cylindroma cells. Am J Pathol (2002) 0.85
Differential geometric analysis of alterations in MH α-helices. J Comput Chem (2013) 0.85